Johnson & Johnson files for European approval of Ebola vaccine

Johnson&Johnson said on Thursday it had filed for an approval from European regulators for its two-dose experimental vaccine to protect against Ebola, less than a month after the agency recommended approval of Merck&Co Inc's vaccine.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

The vaccine provided protection from Ebola virus, Sudan virus, Marburg virus and Lassa virus.
Source: National Institutes of Health (NIH) News Releases - Category: American Health Source Type: news
Data from multiple preclinical, Phase 1, 2 and 3 studies support applications, which have been granted Accelerated Assessment by European Medicines Agency
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV, MVA-BN-Filo vaccine Sponsors:   London School of Hygiene and Tropical Medicine;   Epicentre;   Ministère de la Santé de la RDC;   Médecins Sans Frontières, France;   Coalition for Epidemic Preparedness Innovations;   Janssen Vaccines & Prevention B.V.;   Public Health England Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: BMJ Comments - Category: General Medicine Source Type: forums
The government of the DRC supports use of Janssen ’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
EMA's human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation of individuals aged 18 years and older at risk of infection with the Ebola virus.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news
This article highlights the epidemiology, clinical features, diagnosis, management, and prevention of EVD. The emerging diagnostic technologies, rapid viral characterization, geospatial mapping of EVD transmission, and new treatments and vaccines are discussed.
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
Darwyn Kobasa Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013–2016 West African outbreak. Mouse models of infection are important tools for the development of therapeutics and vaccines. Exposure of immunocompetent mice to clinical isolates of EBOV is nonlethal; consequently, EBOV requires prior adaptation in mice to cause lethal disease. Until now, the only immunocompetent EBOV mouse model was based on the Mayinga variant, which was isolated in 1...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
.
Source: Critical Public Health - Category: International Medicine & Public Health Authors: Source Type: research
Illness is universal, health care is not. Over half of the world’s 7.3 billion people, including 1 billion in rural communities, lack access to health care. Approximately 13 million children still go without a single dose of any vaccine. Nearly 9 million newborns, children and mothers still die each year from preventable or treatable conditions. Compounding this crisis is a massive health-worker shortage, forecast to grow to 18 million by 2030. Training more doctors is necessary, but because doctors are concentrated in cities, they alone are insufficient to close this gap. What if the residents of rural communities&n...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Healthcare Source Type: news
More News: Ebola | Ebola Vaccine | Health | Merck | Vaccines